Loading...
Loading...
BOSTON, MA · CIK 0001346824
New positions
21
Added to
6
Trimmed
13
Exited
13
Current clone valuation is unavailable; this fund is temporarily excluded from rankings. Any chart shown below is the last published snapshot, not recomputed in this refresh. Its historical calculation may use an earlier method.NUVL: current holding price is missing or stale (2026-07-14); NAV not published
Clone performance through . Update overdue — these are historical results, not current market conditions.
Source: SEC 13F-HR filing filed on 2026-11-16 ·View on SEC.gov →
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | $2.34B | 23.50% | - |
| 2 | PBLSPARABILIS MEDICINES INC | $942.16M | 9.45% | +0.8% |
| 3 | PCVXVAXCYTE INC | $652.90M | 6.55% | - |
| 4 | RYTMRHYTHM PHARMACEUTICALS INC | $634.78M | 6.37% | - |
| 5 | EWTXEDGEWISE THERAPEUTICS INC | $340.74M | 3.42% | - |
| 6 | TYRATYRA BIOSCIENCES INC | $266.78M | 2.68% | - |
| 7 | FRNMFREENOME INC | $242.03M | 2.43% | New |
| 8 | COAGHEMAB THERAPEUTICS HOLDINGS | $240.82M | 2.42% | - |
| 9 | NAMSNEWAMSTERDAM PHARMA CO NV | $232.26M | 2.33% | - |
| 10 | SEPNSEPTERNA INC | $215.33M | 2.16% | -21.3% |
| Stock | Value | Shares |
|---|---|---|
| FRNMFREENOME INC | $242.03M | 15,367,270 |
| AMLXAMYLYX PHARMACEUTICALS INC | $124.53M | 4,279,341 |
| WVEWAVE LIFE SCIENCES INC | $99.81M | 26,975,505 |
| LTGOLATIGO BIOTHERAPEUTICS INC | $88.56M | 5,302,933 |
| OBXOBSIDIAN THERAPEUTICS INC | $81.79M | 5,957,103 |
| DAMORA THERAPEUTICS INC | $51.07M | 2,399,702 |
| DBVTDBV TECHNOLOGIES SA-SPON ADR | $43.01M | 3,657,644 |
| AGENAGENUS INC | $40.93M | 4,122,000 |
| SCTXSCRIBE THERAPEUTICS INC | $33.17M | 1,802,178 |
| KRSAKORSANA BIOSCIENCES INC | $28.57M | 892,743 |
As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. reported a portfolio value of $9.97B across 92 positions in their 13F filing.
RA CAPITAL MANAGEMENT, L.P.'s largest holding is ASCENDIS PHARMA A/S with a position worth $2.34B. Their top holdings include ASCENDIS PHARMA A/S, PBLS, PCVX, RYTM, EWTX.
In Q3 2026, RA CAPITAL MANAGEMENT, L.P. made the following changes to their portfolio: 21 new positions, 13 positions sold out, 6 positions increased, 13 positions reduced.
RA CAPITAL MANAGEMENT, L.P. files quarterly 13F reports with the SEC, disclosing their long positions in U.S. equities. These filings are due within 45 days of the quarter end and provide transparency into their investment strategy and portfolio allocation.
One weekly email with notable insider buys, sells and congressional disclosures. Unsubscribe anytime.